329 744

Cited 28 times in

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.

 Hyo Song Kim  ;  Seung Eun Lee  ;  Yoon Sung Bae  ;  Dae Joon Kim  ;  Chang‑Geol Lee  ;  Jin Hur  ;  Hyunsoo Chung  ;  Jun Chul Park  ;  Da Hyun Jung  ;  Sung Kwan Shin  ;  Sang Kil Lee  ;  Yong Chan Lee  ;  Hye Ryun Kim  ;  Yong Wha Moon  ;  Joo Hang Kim  ;  Young Mog Shim  ;  Susan S. Jewell  ;  Hyunki Kim  ;  Yoon-La Choi  ;  Byoung Chul Cho 
 ONCOTARGET , Vol.6(4) : 2562-2572, 2015 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/genetics* ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/therapy ; Disease-Free Survival ; Esophageal Neoplasms/genetics* ; Esophageal Neoplasms/pathology ; Esophageal Neoplasms/therapy ; Female ; Gene Amplification* ; Humans ; In Situ Hybridization, Fluorescence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Prognosis ; Receptor, Fibroblast Growth Factor, Type 1/genetics* ; Risk Factors ; Smoking
Fibroblast growth factor receptor 1 ; esophageal squamous cell carcinoma ; gene amplification ; fluorescent in situ hybridization ; prognostic factor
To investigate the frequency and the prognostic impact of fibroblast growth factor receptor 1 (FGFR1) gene amplification in 526 curatively resected esophageal squamous cell carcinoma (ESCC). Using fluorescent in situ hybridization, high amplification was defined by an FGFR1/centromer 8 ratio is ≥ 2.0, or average number of FGFR1 signals/tumor cell nucleus ≥ 6.0, or percentage of tumor cells containing ≥ 15 FGFR1 signals or large cluster in ≥ 10%. Low amplification was defined by ≥ 5 FGFR1 signals in ≥ 50%. FGFR2 and FGFR3 mutations were assessed by direct sequencing in 388 cases and no mutation was detected. High and low amplification were detected in 8.6% and 1.1%, respectively. High FGFR1 amplification had significantly shorter disease-free survival (34.0 vs 158.5 months P=0.019) and overall survival (52.2 vs not reached P=0.022) than low/no amplification group. After adjusting for sex, smoking, stage, histology, and adjuvant treatment, high FGFR1 amplification had a greater risk of recurrence (adjusted hazard ratio [AHR], 1.6; P=0.029) and death (AHR, 1.53; P=0.050). High amplification was significantly higher in current smokers than former and never-smokers (Ptrend<0.001) and increased proportional to smoking dosage. High FGFR1 amplification is a frequent oncogenic alteration and an independent poor prognostic factor in resected ESCC.
Files in This Item:
T201500960.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Dae Joon(김대준)
Kim, Joo Hang(김주항)
Kim, Hyunki(김현기) ORCID logo https://orcid.org/0000-0003-2292-5584
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Park, Jun Chul(박준철) ORCID logo https://orcid.org/0000-0001-8018-0010
Shin, Sung Kwan(신성관) ORCID logo https://orcid.org/0000-0001-5466-1400
Lee, Sang Kil(이상길) ORCID logo https://orcid.org/0000-0002-0721-0364
Lee, Yong Chan(이용찬) ORCID logo https://orcid.org/0000-0001-8800-6906
Lee, Chang Geol(이창걸) ORCID logo https://orcid.org/0000-0002-8702-881X
Jung, Da Hyun(정다현) ORCID logo https://orcid.org/0000-0001-6668-3113
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Hur, Jin(허진) ORCID logo https://orcid.org/0000-0002-8651-6571
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.